Exogenous VIP limits zymosan-induced generalized inflammation (ZIGI) in mice

Immunology Letters

Volumn 110, Issue 2, 2007, Pages 126-132

  Ivanovska, Nina ^a   Kalfin, Reni ^b   Lazarova, Maria ^b   Dimitrova, Petya ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

Author keywords

Chemokines; Cytokines; Organ injury; VIP; ZIGI

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHEMOKINE; CREATININE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; ZYMOSAN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOGLYCEMIA; IMMUNOBLOTTING; INFLAMMATION; KIDNEY; LIVER; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGAN SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHOCK; SPLEEN; TH2 CELL;

ANIMALS; CYTOKINES; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; ORGAN SIZE; VASOACTIVE INTESTINAL PEPTIDE; ZYMOSAN;

EID: 34249676420     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.04.003     Document Type: Article

References (28)

1. Delgado M., and Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167 (2001) 966-975
2. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 96 (1999) 167-181
3. Delgado M., Munoz-Elias E.J., Martinez C., Gomariz R.P., and Ganea D. VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann NY Acad Sci 897 (1999) 401-414
4. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol 63 (1998) 591-601
5. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162 (1999) 1707-1716
6. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv Neuroimmunol 6 (1996) 61-74
7. Williams R.O. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum 46 (2002) 271-273
8. Delgado M., Munoz-Elias E.J., Kan Y., Gozes I., Fridkin M., Brenneman D.E., et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem 273 (1998) 31427-31436
9. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., and Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 166 (2001) 2522-2530
10. Voice J.K., Grinninger C., Kong Y., Bangale Y., Paul S., and Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T Cell-targeted type ii vip receptor transgenic mice. J Immunol 170 (2003) 308-314
11. Broner C.W., O'Dorisio M.S., Rosenberg R.B., and O'Dorisio T.M. Cyclic nucleotides and vasoactive intestinal peptide production in a rabbit model of Escherichia coli septicemia. Am J Med Sci 309 (1995) 267-277
12. Pannen B.H., and Robotham J.L. The acute-phase response. New Horiz 3 (1995) 183-197
13. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96 (1995) 2339-2347
14. Marchant A., Deviere J., Byl B., De Groote D., Vincent J.L., and Goldman M. Interleukin-10 production during septicaemia. Lancet 343 (1994) 707-708
15. Foey A.D., Field S., Ahmed S., Jain A., Feldmann M., Brennan F.M., et al. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 5 (2003) R317-R328
16. Goris R.J., Boekholtz W.K., van Bebber I.P., Nuytinck J.K., and Schillings P.H. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 121 (1986) 897-901
17. Burdon D., Tiedje T., Pfeffer K., Vollmer E., and Zabel P. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit Care Med 28 (2000) 1962-1967
18. Volman T.J., Hendriks T., Verhofstad A.A., Kullberg B.J., and Goris R.J. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 17 (2002) 468-472
19. Zafirova Y., Yordanov M., and Kalfin R. Antiarthritic effect of VIP in relation to the host resistance against Candida albicans infection. Int Immunol 16 (2004) 1125-1131
20. Jansen M.J., Hendriks T., de Man B.M., van der Meer J.W., and Goris R.J. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Cytokine 11 (1999) 713-721
21. Berg D.J., Leach M.W., Kuhn R., Rajewsky K., Muller W., Davidson N.J., et al. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 182 (1995) 99-108
22. Doherty G.M., Lange J.R., Langstein H.N., Alexander H.R., Buresh C.M., and Norton J.A. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol 149 (1992) 1666-1670
23. Webb D.J., Wen J., Lysiak J.J., Umans L., Van Leuven F., and Gonias S.L. Murine alpha-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-beta and as inducers of nitric oxide synthesis. A possible mechanism for the endotoxin insensitivity of the alpha2-macroglobulin gene knock-out mouse. J Biol Chem 271 (1996) 24982-24988
24. Baggiolini M. Chemokines and leukocyte traffic. Nature 392 (1998) 565-568
25. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
26. VanOtteren G.M., Strieter R.M., Kunkel S.L., Paine III R., Greenberger M.J., Danforth J.M., et al. Compartmentalized expression of RANTES in a murine model of endotoxemia. J Immunol 154 (1995) 1900-1908
27. Fisher N.C., Neil D.A., Williams A., and Adams D.H. Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease. Gut 45 (1999) 416-420
28. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003) 138-150